Bioxyne expands LATAM medicinal cannabis footprint with Costa Rica agreement

• First supply agreement for medicinal cannabis flower to Costa Rica
• Expanded supply agreement to supply three Dr Watson cannabis flower stock keeping units
• Represents first international supply of medicinal cannabis flower in Costa Rica
• Initial shipment to be made prior to 30 June 2026

Australian pharmaceutical company Bioxyne (ASX: BXN) has signed an agreement for the first international supply of medicinal cannabis flower into Costa Rica’s regulated market.

Through wholly-owned subsidiary Breathe Life Sciences (BLS), the company has executed an expanded supply agreement with Remidose LATAM SRL to include the supply of three Dr Watson cannabis flower SKUs to Costa Rica.

CEO, Sam Watson, said the expansion of an initial December 2025 agreement to include cannabis flower, highlights strong early-stage demand and reinforces the strategic alignment between Bioxyne and Remidose.

Under the expanded agreement Bioxyne will also supply cannabis pastilles for distribution into Costa Rica and Panama, further strengthening Bioxyne’s presence across LATAM markets.

“This expansion with Remidose is a great example of how quickly opportunities can evolve once you establish a presence in new markets,” Mr Watson said.

“We’ve moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we’re seeing on the ground.

“LATAM is still early in its development, but that’s exactly where we see the opportunity. Being the first to supply branded medicinal cannabis flower into Costa Rica positions us ahead of competing suppliers and gives us the platform to expand into other LATAM jurisdictions as those markets continue to open.”

Mr Watson said product registration for Costa Rica is well advanced and initial shipments of Dr Watson cannabis flower are expected prior to 30 June 2026, with the first shipment to exceed $500,000.

Based on current demand forecasts, he said the company expects repeat orders, subject to market conditions and regulatory approvals.

Remidose MD, Michael Mayne, said early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market.

Mr Watson said Costa Rica represents an early-stage regulated medicinal cannabis market with limited competition and significant long-term growth potential, supported by evolving regulatory frameworks and increasing patient access.

BXN is steady at 1.8¢. Mkt cap $12.60M.

Join the discussion: See what Hot Copper users are saying about Bioxyne and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.